Corporate Lawyer Focusing on Venture Formation and Financing, Mergers and Acquisitions and Commercial and IP Agreements | External GC
"The pandemic experience was supposed to be a boon for direct-to-consumer disease treatments, digital therapeutics and decentralized care. But adoption turned out to be much slower than expected, and massive failures such as Pear Therapeutics sent investors scrambling for the exits. The big picture: The outlook could be improving for a few digital health companies — especially those offering novel uses of artificial intelligence." At the end of the day, it all comes down to adoption. My dad tells a story. A company launched a new cat food that would address a nutritional deficiency in existing cat foods on the market. Everybody loved the cat food – sales, marketing, everybody in the C-Suite, and the board of directors. The salespeople had no problem getting shelf space for the cat food and competitors announced their intention to launch competing products. Cat owners eagerly snapped up the cat food. However, there was one small problem. The cats would not eat the cat food. In healthcare so many promising ideas seem to die because the healthcare professionals will not adopt them. Increasing the likelihood of adoption is a critical part of each startup's business plan.
